No21Vol1.indd

Similar documents
: / FDA HBsAg HIV 1/2 HCV : QMS : 3.5% IgM () 1.0% H317 - H334 - : : :: : QMS Everolimus : 6.4% (II) H400 - H % SDS QMS EDTA (K 3 ) EDTA (K 2 )

腎不全-第22回.indd

Taro12-認定-部門-ASG101-06

18 20 A1c C HDL-LDL-C- A1c C CRP CRP ID-MS RF(PRL)(LH) (FSH)E2TSH -(hcg) AFPCEA)(FCM) RFPRLE2TSHhCGAFP CEA

JIS Z 9001:1998JIS Z 9002:1998 ISO/IEC 17025ISO/IEC Guide 25

-. -. CD Threshold Noise Discrimination CD CDbight+ CDdim CD は



untitled

untitled

SI SI CIPM MRA

untitled


表1.eps

JAMSTEC Rep. Res. Dev., Volume 12, March 2011, 27 _ 35 1,2* Pb 210 Pb 214 Pb MCA 210 Pb MCA MCA 210 Pb 214 Pb * 2



FREE

NGGAUM_特別対談_再.indd

BC2007_11_ indd



HPV HPV HPV HPV 7 HPV 8 9 HPV 3 HPV HPV HPV , Becker Ajzen H

O-1 O-2 O-3 O-4 O-5 O-6

ドコモP-01Hカタログ

The Heart Healthy Tocotrienol Complex Tocomin SupraBio

国際的血球基準器としてのコールターカウンターモデルZBIの機能



CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

MRA CIPM-MRA Mutual Recognition Arrangement OIML-MAA Mutual Acceptance Arrangement ILAC-MRA 3 CIPM-MRA (Associate to CGPM)+2 (As o


平成26年度 化学物質分析法開発報告書

DETECTION OF PROSTATE CANCER IN UROLOGICAL PRACTICE: Clinical Establishment of Serum PSA Reference Values by Age Haruki Yamazaki, Yasuyuki Suzuki, Ats

untitled

この添付文書をよく読んでから使用してください 体外診断用医薬品 ** 2018 年 3 月改訂 ( 第 6 版 ) * 2017 年 9 月改訂 ( 第 5 版 ) 製造販売承認番号 21200AMY 遊離型前立腺特異抗原キット フリー PSA アボット ja Free PSA 7K

FIBA In Memoriam

がん患者の終末期ケアにおける通所リハビリテーションの役割 介護保険によるがん終末期ケアの可能性

X線分析の進歩36 別刷

平成26年度 化学物質分析法開発報告書




野岩鉄道の旅

表紙_02

スライド タイトルなし

免疫Ⅱ

GJG160842_O.QXD

3 1 2

04菊池氏.indd

1


スタイルシェルフ 〈クローク収納プラン〉

2

<31332D97708CEA89F090E02E6D6364>


マイスタープロジェクト 推奨仕様

第18回海岸シンポジウム報告書


3

(718)


液晶ディスプレイ取説TD-E432/TD-E502/TD-E552/TD-E652/TD-E432D/TD-E502D


() () ()

000-.\..


1 C 2 C 3 C 4 C 1 C 2 C 3 C

<967B95D2955C8E F4390B32E6169>


平成24年財政投融資計画PDF出後8/016‐030


Green Light GxP HPLC 2

437“ƒ

5 CSF 6 CSF 7 CSF CSF CDV CDV GFAP CSF Pandy test NSE MBP LDH mu/ml 0-5 /µl AST mu/ml CK mu/ml <25 mg/dl<45 mg/dl GLU

NL16-1_0329


JAB RL504:201 JAB NOTE 4 2 January 25, A B

GB 3rd edition final.ppt

flF™m…−…n„Efic’æ’¶

CA CA19-9 CA19-9 CA CA CA19-9 ARCHITECT i 2000SR CLIA U/mL CA % CA CA

DocHdl1OnPRS1tmpTarget

. 1 EBM Evidence-Based Medicine JCAHO 2

CH 2 CH CH 2 CH CH 2 CH CH 2 CH 2 COONa CH 2 N CH 2 COONa O Co 2+ O CO CH 2 CH N 2 CH 2 CO 9 Change in Ionic Form of IDA resin with h ph CH 2 NH + COO

untitled

untitled

Steel Construction Engineering Vol.3 No.12(December 1996)

臨床神経45-1.indb

356 Nippon Shokuhin Kagaku Kogaku Kaishi Vol. /., No.1, -/0-0+ (,**1) 44 For Quality Control and Quality Assurance in Food Analysis Akemi Yasui Analyt

VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3

Japanese.PDF

TissueGnostics HistoFAXS TissueGnostics HistoFAXS HistoFAXS 最新の技術に裏づけられた細胞解析システム HistoFAXS HistoFAXS HistoFAXS HistoFAXS Zeiss 2 HistoFAXS HistoQuest


000..\..

(印刷)分身主義の森を抜けて‥‥

審査報告書(案)

VOL. 21 NO. 2 CHEMOTHERAPY 395

Unknown


Letter566.pdf

Transcription:

( ): - PSA Shojiro Kano Head, Working Group of PSA Testing Standardization Committee (PSA) PSA PSA JCCLS PSA A PSA B PSA PSA Wang PSA FDA Hybritech Tandem-R PSA

PSA PSA PSA - (ACT) - (AMG) ACT (PSA-ACT) PSA PSA (Free PSA) PSA-ACT, PSA-ACT PSA PSA-ACT Free PSA PSA (Total PSA) PSA PSA PSA Stanford NCCLS PSA PSA PSA PSA PSA-ACT PSA-ACT PSA-ACT Free PSA : : standard WHO IFCC (primary standard) NIBSC PSA PSA Tandem-R PSA PSA Free PSA (skewed response) PSA Free PSA PSA-ACT (equimolar response) PSA PSA ( )

Stanford Free PSA PSA- ACT Free PSA PSA-ACT Free PSA PSA-ACT PSA ad hoc ( ) Free PSA PSA-ACT - ) PSA ( ) PSA : standard ( ) (JCCLS) PSA ( ) PSA - ) PSA PSA PSA PSA AMG AMG Zn Hybritech ( ) Free PSA AMG ph. M NaOH ph. M HCl

ph.. mm - ) ( ) PSA Free PSA PSA-ACT consensus method PSA - ) ( ) C ( ) ( ) Stanford Free PSA PSA-ACT.. ng/ml ( ) (Free PSA PSA-ACT ) ( ). ( ) ( ) PSA (Free PSA PSA- ACT) ( ) ( ) ( )

PSA PSA-ACT Free PSA PSA-ACT Free PSA PSA-ACT - ) ELISA ( : standard) PSA AMG PSA PSA WHO PSA WHO PSA

PSA PSA PSA PSA Free PSA PSA-ACT PSA SR ( ) ( ) ( ) ( ) ( SR ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Lilja H, Christensson A, Dahlen U, et al: Prostate-specifi c antigen in serum occurs predominantly in complex with a -antichymotrypsin Clin Chem., : -,. Stenman UH, Leinonen J, Alfthan H, et al: A complex between prostate specifi c antigen and a -antichymotrypsin is the major form of prostate specifi c antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer Cancer Res., : -,. NCCLS Primary Reference Preparations Used to Standardize Calibration of Immunochemical Assays for Serum Prostate Specifi c Antigen (PSA); Approved Guideline NCCLS document I/LA -A NCCLS, Pennsylvania, USA,. PSA, : -,. PSA PSA ad hoc, : -,. PSA PSA

, ( ): -,. S Kano, M Ishibashi, K Kuwa, Y Itoh, W Tani, K Shimazu, K Abe, K Fujihashi and T Yoshikai: Successful Preparation of Serum-Based Secondary Reference Material for Standardization of Total Prostate-Specific Antigen (PSA) Immunoassays Proceeding of th European Congress of Clinical Chemistry and Laboratory Medicine, -,. PSA, (S ), -,. A PSA ) ) ) ( SR ( SR ) B:PSA WG JCCLS WG Dr. Harry G. Rittenhouse (Beckman Coulter, Inc) ICCC Kyoto Luncheon seminar

PSA standardization; biochemical & analytical implication WG ICCC Kyoto Dr. Robert M. Nakamura (Scripps Clinic) JCCLS WG JCCLS WG Dr. Sephen D. Mikolajczyk (Hybritech; Beckman Coulter Inc) prostatespecific antigen (total PSA) ( ) PSA Dr. Peter Bialk (Roche Diagnostics GmbH) WG EuroMedLab Barcelona Successful preparation of serumbased secondary reference material for standardization of total prostate-specifi c antigen (PSA) immunoassays WG WG WG WG Survey

WG WG Survey WG WG JCCLS WG WG WG C. PSA. Survey. Survey. Survey..... Base Buffer Base Serum... Free PSA PSA-ACT. Free PSA (A) (B, B')... Free PSA (A).. (,,,, ) (C ). (C)........ (C ) (C C ). Outlyer (C ) (C C ). Precision Profile. Precision Profile Outlyer